• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    27.20 +0.10 (+0.37%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Royalty Pharma Plc Cl A

    < Previous 1 2 3 4 5 6 7 Next >
    How To Attend Royalty Pharma Q1 2022 Earnings Conference Call
    Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
    Upgrades 
    Via Benzinga
    The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
    Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
    Via Benzinga
    Exposures Product Safety
    Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
    Upgrades 
    Via Benzinga
    Expedia And 3 Other Stocks Insiders Are Selling
    Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
    Via Benzinga
    Hopeful Golden Cross Forms On Royalty Pharma's Chart
    If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
    Via Benzinga
    Looking Into Royalty Pharma's Return On Capital Employed
    According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%... 
    Via Benzinga
    The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
    Via Benzinga
    ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
    ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital... 
    Via Benzinga
    DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger
    Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. 
    Via InvestorPlace
    Earnings Scheduled For February 15, 2022
    Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
    Via Benzinga
    2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
    The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market... 
    Via Benzinga
    Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: 
    Via Benzinga
    BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
    Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals... 
    Via Benzinga
    Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
    Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. 
    Via InvestorPlace
    36 Stocks Moving in Tuesday's Pre-Market Session
    Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
    Via Benzinga
    Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript
    RPRX earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
    Upgrades For Preferred Bank (NASDAQ: 
    Via Benzinga
    AstraZeneca's Two Asthma Trials Meet Primary Endpoints
    Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of... 
    Via Benzinga
    Cramer Gives His Opinion On Applied Materials, Coinbase And More
    On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter. People who were selling the stock didn... 
    Via Benzinga
    Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
    Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and... 
    Via Benzinga
    Royal Pharma (RPRX) Q2 2021 Earnings Call Transcript
    RPRX earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Recap: Royalty Pharma Q2 Earnings
    Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year... 
    Via Benzinga
    The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
    Via Benzinga
    Exposures Product Safety
    Earnings Scheduled For August 11, 2021
    Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... 
    Via Benzinga
    Why MorphoSys Stock Sank This Week
    Investors weren't happy about the drugmaker's wheeling and dealing. 
    Via The Motley Fool
    Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover
    MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.